A new study conducted by researchers from the Corrine Goldsmith Dickinson Center for Multiple Sclerosis at Icahn School of Medicine at Mount Sinai in collaboration with Novartis, the University of ...

Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It can cause fatigue, trouble with balance and coordination, muscle weakness, and vision problems. Having MS doesn’t ...

– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

A phase 3 study has shown that tolebrutinib, a drug being tested in treating non-relapsing secondary progressive multiple sclerosis, slowed the progression of disability in patients. The trial ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple sclerosis ...

Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.

The symptoms of multiple sclerosis (MS) can vary. People with MS symptoms that prevent them from working and doing other everyday tasks can often qualify for disability benefits and services. Multiple ...